Meropenem Sun (Meropenem Anhydrous)

Meropenem Sun is a carbapenem antibiotic used to treat serious bacterial infections across several organ systems.

• Complicated intra‑abdominal infections: provides effective therapy against mixed aerobic and anaerobic pathogens.
• Complicated urinary tract infections: eradicates susceptible Gram‑negative and Gram‑positive organisms.
• Bacterial meningitis: achieves high cerebrospinal fluid concentrations to treat meningitic pathogens.
• Severe sepsis: offers broad‑spectrum coverage for life‑threatening systemic infections.
• Hospital‑acquired pneumonia: targets resistant organisms commonly encountered in nosocomial lung infections.

• Meropenem binds to penicillin‑binding proteins (PBPs) on bacterial cell walls, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic lysis and bacterial death. The molecule is resistant to most β‑lactamases, providing activity against a wide range of Gram‑negative, Gram‑positive, and anaerobic bacteria.

Adverse reactions may occur with any intravenous antibiotic and should be monitored during therapy.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Vomiting: occasional emesis during infusion.
• Headache: transient cranial discomfort.
• Infusion site phlebitis: redness or pain at the catheter site.
• Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or CNS disorders.
• Anaphylaxis: severe allergic reaction requiring immediate intervention.
• Clostridioides difficile colitis: antibiotic‑associated colitis.
• Neutropenia: marked reduction in neutrophil count.
• Thrombocytopenia: low platelet levels.
• Acute renal impairment: worsening kidney function during therapy.

Careful assessment and monitoring are required before and during treatment with Meropenem Sun.

• Renal function: dose adjustment may be necessary in patients with impaired kidney function.
• Hepatic function: monitor liver enzymes, especially in patients with pre‑existing liver disease.
• Seizure risk: avoid or use with caution in patients with a history of seizures or CNS disorders.
• Valproic acid co‑administration: may reduce valproate levels and increase seizure risk.
• Pregnancy: safety not established; use only if the potential benefit justifies the potential risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem Sun can interact with several drugs, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Valproic acid: may lower serum valproate concentrations, increasing seizure risk.
• Concurrent carbapenems: duplication of therapy provides no added benefit and may increase toxicity.
• High‑dose aminoglycosides: combined nephrotoxic potential.

Moderate Interactions (Monitor Closely)

• Loop diuretics: may exacerbate renal dysfunction.
• NSAIDs: can affect renal clearance of meropenem.
• Warfarin: may alter INR, requiring closer coagulation monitoring.
• Probenecid: can decrease renal excretion of meropenem, raising plasma levels.